Oxford vaccine shows positive results in clinical trials

Oxford vaccine shows positive results in clinical trials. ChAdOx1 nCoV-19, called AZD-1222, developed by Oxford University against coronavirus started in January 2020. The Oxford University vaccine collaborating with AstraZeneca declared the original data and conclusions on the vaccine’s efficacy. The vaccine applicant that was one of the first contestants to have reached the clinical trial stage is undergoing phase 3 of the clinical trials somewhere in Brazil. Generated at the Jenner Institute, ChAdOx1 nCoV-19 utilizes a viral vector based on a relaxed version of the common cold virus (adenovirus) comprising the genetic element of the SARS-CoV-2 spike protein.